Oramed Pharmaceuticals (ORMP)
(Real Time Quote from BATS)
$2.36 USD
+0.02 (0.86%)
Updated Nov 7, 2024 01:40 PM ET
NA Value
NA Growth NA Momentum NA VGMOramed Pharmaceuticals (ORMP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.25 | $3.25 | $3.25 | 38.89% |
Price Target
Only one analyst offered a short-term price target of $3.25 for Oramed Pharmaceuticals. This represents an increase of 38.89% from the last closing price of $2.34.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Hold-equivalent recommendation for Oramed Pharmaceuticals. This translates to an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 3.00 a month ago based on just one recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/9/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 1 |
Average Target Price | $3.25 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | 0.01 |
ORMP FAQs
Oramed Pharmaceuticals Inc. (ORMP) currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 1 brokerage firms.
The average price target for Oramed Pharmaceuticals Inc. (ORMP) is $3.25. The current on short-term price targets is based on 2 reports.
The forecasts for Oramed Pharmaceuticals Inc. (ORMP) range from a low of $3.25 to a high of $3.25. The average price target represents a increase of $38.89 from the last closing price of $2.34.
The current UPSIDE for Oramed Pharmaceuticals Inc. (ORMP) is 38.89%
Only one analyst offered a short-term price target of $3.25 for Oramed Pharmaceuticals. This represents an increase of 38.89% from the last closing price of $2.34.